These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 16751787)

  • 21. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation.
    Al-Hazzouri A; Cao Q; Burns LJ; Weisdorf DJ; Majhail NS
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):658-63. PubMed ID: 18489991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low mortality of children undergoing hematopoietic stem cell transplantation from 7 to 8/10 human leukocyte antigen allele-matched unrelated donors with the use of antithymocyte globulin.
    Sedlácek P; Formánková R; Keslová P; Srámková L; Hubácek P; Król L; Kulich M; Starý J
    Bone Marrow Transplant; 2006 Dec; 38(11):745-50. PubMed ID: 17041606
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning.
    Uzunel M; Remberger M; Sairafi D; Hassan Z; Mattsson J; Omazic B; Barkholt L; Ringdén O
    Transplantation; 2006 Oct; 82(7):913-9. PubMed ID: 17038906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Non-myeloablative allogeneic stem cell transplantation].
    Dalgaard J; Fløisand Y; Stenersen M; Egeland T; Brinch L
    Tidsskr Nor Laegeforen; 2007 Mar; 127(6):721-4. PubMed ID: 17363982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral cyclosporine A treatment is feasible after myeloablative conditioning in allogeneic hematopoietic stem cell transplantation.
    Nygaard M; Hovgaard D; Schjødt IM; Andersen NS; Vindeløv L; Sengeløv H
    J Clin Pharm Ther; 2015 Jun; 40(3):358-61. PubMed ID: 25829023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Graft-versus-host disease of the kidney after rapid tapering of cyclosporin following reduced intensity hematopoietic stem cell transplantation.
    Homma CI; Kami M; Masuo S; Sakiyama M; Kojima R; Hori A; Kusumi E; Katori H; Takeuchi K; Kishi Y; Murashige N; Kim SW; Takaue Y; Mitamura T
    Bone Marrow Transplant; 2005 May; 35(9):929-30. PubMed ID: 15765112
    [No Abstract]   [Full Text] [Related]  

  • 28. Recent progress in allogeneic stem cell transplantation.
    Mattsson J
    Curr Opin Mol Ther; 2008 Aug; 10(4):343-9. PubMed ID: 18683098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Importance of CsA drug monitoring in SCT recipients to minimize GVHD and maximize graft vs. leukemia.
    Barkholt L
    Pediatr Transplant; 2009 Jun; 13(4):400-3. PubMed ID: 18992059
    [No Abstract]   [Full Text] [Related]  

  • 30. Optimal use of G-CSF administration after hematopoietic SCT.
    Trivedi M; Martinez S; Corringham S; Medley K; Ball ED
    Bone Marrow Transplant; 2009 Jun; 43(12):895-908. PubMed ID: 19363527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia/lymphoma: impact of antithymocyte globulin on clinical outcome.
    Tanosaki R; Uike N; Utsunomiya A; Saburi Y; Masuda M; Tomonaga M; Eto T; Hidaka M; Harada M; Choi I; Yamanaka T; Kannagi M; Matsuoka M; Okamura J
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):702-8. PubMed ID: 18489996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON).
    Muñoz A; Olivé T; Martinez A; Bureo E; Maldonado MS; Diaz de Heredia C; Sastre A; Gonzalez-Vicent M;
    Pediatr Hematol Oncol; 2007 Sep; 24(6):393-402. PubMed ID: 17710656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The measurement of whole blood pre-treatment cyclosporine A: metabolite ratios predicts the onset of renal dysfunction in recipients of allogeneic stem cell transplantation.
    Stephens E; Bolderson I; Clark B; Kinsey S; Gooi HC; Cook G
    Ann Clin Biochem; 2006 Sep; 43(Pt 5):382-8. PubMed ID: 17022881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allogeneic transplantation in lymphoma: current status.
    Schmitz N; Dreger P; Glass B; Sureda A
    Haematologica; 2007 Nov; 92(11):1533-48. PubMed ID: 18024402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Continuous infusion of cyclosporine A and C3 monitoring in pediatric stem cell transplantation].
    Matsubara H; Kobayashi M; Yui Y; Kato I; Niwa A; Arai M; Miyazaki M; Mizushima Y; Umeda K; Hiramatsu H; Watanabe K; Adachi S; Nakahata T
    Rinsho Ketsueki; 2007 Aug; 48(8):605-10. PubMed ID: 17867295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bone marrow transplantation: new approaches to immunosuppression and management of acute graft-versus-host disease.
    Auletta JJ; Cooke KR
    Curr Opin Pediatr; 2009 Feb; 21(1):30-8. PubMed ID: 19242239
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post-allogeneic haematopoietic stem cell transplantation membranous nephropathy: clinical presentation, outcome and pathogenic aspects.
    Terrier B; Delmas Y; Hummel A; Presne C; Glowacki F; Knebelmann B; Combe C; Lesavre P; Maillard N; Noël LH; Patey-Mariaud de Serre N; Nusbaum S; Radford I; Buzyn A; Fakhouri F
    Nephrol Dial Transplant; 2007 May; 22(5):1369-76. PubMed ID: 17255123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival.
    Norlin AC; Sairafi D; Mattsson J; Ljungman P; Ringdén O; Remberger M
    Bone Marrow Transplant; 2008 Feb; 41(3):267-73. PubMed ID: 17994123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
    Blau IW; Schmidt-Hieber M; Leschinger N; Göldner H; Knauf W; Hopfenmüller W; Thiel E; Blau O
    Ann Hematol; 2007 Aug; 86(8):583-9. PubMed ID: 17468869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.